Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme

Ensartinib (X-396) is a promising tyrosine kinase inhibitor currently undergoing advanced clinical evaluation for the treatment of non-small cell lung cancer. In this work, we investigate possible interactions of this promising drug candidate with ATP-binding cassette (ABC) drug efflux transporters...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Vagiannis, Dimitrios, Novotna, Eva, Skarka, Adam, Kammerer, Sarah, Küpper, Jan-Heiner, Chen, Si, Guo, Lei, Staud, Frantisek, Hofman, Jakub
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226045/
https://ncbi.nlm.nih.gov/pubmed/32231067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040813
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados